# AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus

> **NCT00241605** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 600 (—)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** rosiglitazone/metformin

## Key facts

- **NCT ID:** NCT00241605
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06-25
- **Primary completion:** 2005-12-01
- **Final completion:** 2005-12-16
- **Target enrollment:** 600 (—)
- **Last updated:** 2018-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00241605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00241605, "AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00241605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*